Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case

Akira Hirasawa, Kenta Masuda, Tomoko Akahane, Arisa Ueki, Megumi Yokota, Tomohiko Tsuruta, Hiroyuki Nomura, Fumio Kataoka, Eiichirou Tominaga, Kouji Banno, Kazuya Makita, Nobuyuki Susumu, Kokichi Sugano, Kenjiro Kosaki, Kaori Kameyama, Daisuke Aoki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer. Methods: One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer. Results: Nine of 102 (8.8%) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0%) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingooophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case. Conclusions: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.

Original languageEnglish
Article numberhyt171
Pages (from-to)49-56
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Fingerprint

Ovarian Neoplasms
Fallopian Tube Neoplasms
Neoplasms
Mutation
Hereditary Breast and Ovarian Cancer Syndrome
Laser Capture Microdissection
Hereditary Nonpolyposis Colorectal Neoplasms
Fallopian Tubes
Histology
Carcinogenesis
Cross-Sectional Studies
Epithelial Cells
Population

Keywords

  • Fallopian tube epithelium
  • Family history
  • Hereditary breast-ovarian cancer
  • Lynch syndrome
  • Occult cancer
  • Ovarian cancer
  • p53 signature
  • Risk-reducing salpingo-oophorectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case. / Hirasawa, Akira; Masuda, Kenta; Akahane, Tomoko; Ueki, Arisa; Yokota, Megumi; Tsuruta, Tomohiko; Nomura, Hiroyuki; Kataoka, Fumio; Tominaga, Eiichirou; Banno, Kouji; Makita, Kazuya; Susumu, Nobuyuki; Sugano, Kokichi; Kosaki, Kenjiro; Kameyama, Kaori; Aoki, Daisuke.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 1, hyt171, 01.2014, p. 49-56.

Research output: Contribution to journalArticle

Hirasawa, Akira ; Masuda, Kenta ; Akahane, Tomoko ; Ueki, Arisa ; Yokota, Megumi ; Tsuruta, Tomohiko ; Nomura, Hiroyuki ; Kataoka, Fumio ; Tominaga, Eiichirou ; Banno, Kouji ; Makita, Kazuya ; Susumu, Nobuyuki ; Sugano, Kokichi ; Kosaki, Kenjiro ; Kameyama, Kaori ; Aoki, Daisuke. / Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case. In: Japanese Journal of Clinical Oncology. 2014 ; Vol. 44, No. 1. pp. 49-56.
@article{0e6b55d7be764fadbd7ebbd3b2f9770c,
title = "Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case",
abstract = "Background: This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer. Methods: One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer. Results: Nine of 102 (8.8{\%}) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0{\%}) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingooophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case. Conclusions: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.",
keywords = "Fallopian tube epithelium, Family history, Hereditary breast-ovarian cancer, Lynch syndrome, Occult cancer, Ovarian cancer, p53 signature, Risk-reducing salpingo-oophorectomy",
author = "Akira Hirasawa and Kenta Masuda and Tomoko Akahane and Arisa Ueki and Megumi Yokota and Tomohiko Tsuruta and Hiroyuki Nomura and Fumio Kataoka and Eiichirou Tominaga and Kouji Banno and Kazuya Makita and Nobuyuki Susumu and Kokichi Sugano and Kenjiro Kosaki and Kaori Kameyama and Daisuke Aoki",
year = "2014",
month = "1",
doi = "10.1093/jjco/hyt171",
language = "English",
volume = "44",
pages = "49--56",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case

AU - Hirasawa, Akira

AU - Masuda, Kenta

AU - Akahane, Tomoko

AU - Ueki, Arisa

AU - Yokota, Megumi

AU - Tsuruta, Tomohiko

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Tominaga, Eiichirou

AU - Banno, Kouji

AU - Makita, Kazuya

AU - Susumu, Nobuyuki

AU - Sugano, Kokichi

AU - Kosaki, Kenjiro

AU - Kameyama, Kaori

AU - Aoki, Daisuke

PY - 2014/1

Y1 - 2014/1

N2 - Background: This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer. Methods: One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer. Results: Nine of 102 (8.8%) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0%) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingooophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case. Conclusions: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.

AB - Background: This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer. Methods: One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer. Results: Nine of 102 (8.8%) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0%) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingooophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case. Conclusions: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.

KW - Fallopian tube epithelium

KW - Family history

KW - Hereditary breast-ovarian cancer

KW - Lynch syndrome

KW - Occult cancer

KW - Ovarian cancer

KW - p53 signature

KW - Risk-reducing salpingo-oophorectomy

UR - http://www.scopus.com/inward/record.url?scp=84892457930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892457930&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt171

DO - 10.1093/jjco/hyt171

M3 - Article

AN - SCOPUS:84892457930

VL - 44

SP - 49

EP - 56

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

M1 - hyt171

ER -